Sunshine Biopharma (SBFM, Financial), through its wholly owned subsidiary Nora Pharma, has introduced Everolimus to the Canadian generic prescription drug market. Everolimus serves as a cost-effective alternative to the branded drug Afinitor, offering a significant treatment option for various cancers.
This generic drug is indicated for use in managing advanced renal cell carcinoma and breast cancer in post-menopausal women who have the advanced HER2-negative genotype. Additionally, Everolimus is prescribed for treating progressive well or moderately differentiated neuroendocrine tumors that originate in the pancreas, gastrointestinal tract, or lungs. It also addresses subependymal giant cell astrocytoma linked to tuberous sclerosis complex.
Available in three different dosages—2.5 mg, 5 mg, and 10 mg—Nora Pharma's Everolimus is supplied in blister packs containing 30 tablets each. This launch marks a strategic expansion for Sunshine Biopharma into the Canadian pharmaceutical market, potentially enhancing access to crucial cancer therapies.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Sunshine Biopharma Inc (SBFM, Financial) is $300.00 with a high estimate of $300.00 and a low estimate of $300.00. The average target implies an upside of 23,900.00% from the current price of $1.25. More detailed estimate data can be found on the Sunshine Biopharma Inc (SBFM) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Sunshine Biopharma Inc's (SBFM, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Sunshine Biopharma Inc (SBFM, Financial) in one year is $236.50, suggesting a upside of 18820% from the current price of $1.25. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Sunshine Biopharma Inc (SBFM) Summary page.
